Skip to content
  • About us
    • Overview
    • Our founders
    • Careers
  • Our pipeline
    • Development pipeline
    • Netazepide
      • Background
      • Studies
      • Further studies
    • Ceclazepide
    • TR4
    • TR8
  • Trio Medicines Logo
  • Our publications
  • Contact us
Previous Next

The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.

Webb DL, Rudholm-Feldreich T, Gillberg L, Halim MA, Theodorsson E, Sanger GJ, Campbell CA, Boyce M, Näslund E, Hellström PM.  The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.  Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 41–49.

 

myarzi12019-03-26T13:20:31+00:00Netazepide|

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditGoogle+TumblrPinterestVkEmail